

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

37. *Chen et al.* 2005

2. Prostaglandins associated with the Cyclooxygenase function

23524

24

1. The number of items in the list must be greater than zero.

[illegible]

2.5. *Chloroacetic acid, chloroacetic anhydride, and chloroacetic anhydride*. Anhydride

14

The subjects assigned with Vitamin Nourish

23524

DA

2007年12月15日

5552

100

100

Copyright © 2004 John Wiley & Sons, Inc.

Yamazaki Holdings, LLC
2711 Centerville Road
Suite 400
Wilmington, Delaware 19808

A copy of this form, together with a statement under 37 CFR 2.73(b) (Form PTO/SB-96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 2.73(b) may be completed by one of the practitioners who is appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and no agent; if the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is required is set out in detail in the schedule

Symptoms

2254

12-15-2011 10:00 AM

Date: 11/11/2011

Yamamoto, Y.


228

[illegible][illegible]

If you would like to receive this e-mail, please click on the link below to confirm your subscription.

DECLARATION REGARDING AUTHORITY TO SIGN ON BEHALF OF A LEGAL ENTITY
(37 C.F.R. 5.73(b)(9)(i))

I, Russell Bolwood (whose title is supplied below), hereby declare that I am authorized to sign on behalf of Yamazaki Holdings, LLC.



Russell Bolwood
Authorized Person for Yamazaki Holdings, LLC

LYDIA BOLWOOD
[Name]